MedTrace Logo

Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial

NCT04662684 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2022-04-06

No results posted yet for this study

Summary

The Michelle trial is expected to provide high-quality evidence around the role of extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.

Conditions

  • Covid19
  • Venous Thromboembolism

Interventions

DRUG

Rivaroxaban 10 MG

No intervention

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Science Valley Research Institute

    lead OTHER

Principal Investigators

  • Eduardo Ramacciotti, MD, Ph.D · Science Valley Research Institute

  • Leandro Agati, PhD · Science Valley Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-16
Primary Completion
2021-07-10
Completion
2021-08-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04662684 on ClinicalTrials.gov